|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Schizophrenia | |||||
| 2 | More general conditions related to this trial | ||||
| Mental Disorders | |||||
| Schizophrenia and Disorders with Psychotic Features | |||||
| 3 | Interventions listed in this trial | ||||
| Cognitive remediation | |||||
| Health behavior training | |||||
| Risperidone, administered orally | |||||
| Individual Placement and Support | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Risperidone | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antipsychotic Agents | |||||
| Central Nervous System Agents | |||||
| Central Nervous System Depressants | |||||
| Dopamine Agents | |||||
| Dopamine Antagonists | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Psychotropic Drugs | |||||
| Serotonin Agents | |||||
| Serotonin Antagonists | |||||
| Therapeutic Uses | |||||
| Tranquilizing Agents | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||